[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.211.120.181. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Editorial
September 27, 2006

Explaining, Predicting, and Treating HIV-Associated CD4 Cell LossAfter 25 Years Still a Puzzle

Author Affiliations
 

Author Affiliations: HIV Program, Hennepin County Medical Center and the University of Minnesota, Minneapolis (Dr Henry); Division of Infectious Diseases, University of Pennsylvania, Philadelphia (Dr Tebas); and Division of Clinical Research and Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, Bethesda, Md (Dr Lane).

JAMA. 2006;296(12):1523-1525. doi:10.1001/jama.296.12.1523

The clinical syndrome of AIDS is due to infection with the human immunodeficiency virus (HIV), which causes a progressive immunodeficiency characterized by the loss of CD4 T lymphocytes coupled with an immunosuppression related to global activation of the immune system. Since the seminal article by Mellors et al in 1996,1 it has been known that as a group, individuals with a higher HIV RNA viral load tend to progress to AIDS and death at a more rapid rate than those with lower viral loads, and that different prognostic information can be derived from the CD4 cell count and the viral load. The conventional wisdom is that the CD4 cell count represents the current state of immune deficiency, whereas the viral load reflects the rate at which the immune system will further deteriorate.2

First Page Preview View Large
First page PDF preview
First page PDF preview
×